Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream

Main Article Content

Linda Stein Gold
Dermatology Clinical Research, Henry Ford Health System, Detroit, Michigan, USA

Andreas Pinter
Dept. of Dermatology, Venereology and Allergology, University Hospital Frankfurt/Main, Frankfurt/Main, Germany

April Armstrong
Keck School of Medicine, Department of Dermatology, University of Southern California Los Angeles, USA

Lars Iversen
MC2 Therapeutics, Hørsholm, Denmark

Morten Praestegaard
MC2 Therapeutics, Hørsholm, Denmark

Matthias Augustin
University Medical CenterHamburg-Eppendorf, Hamburg, Germany

Keywords

Calcipotriene, Betamethasone diproprionate, Cream, Topical, Psoriasis

References

1. Praestegaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug oenetration, local tolerability and convenience of application. Dermal Ther (Heidelb). 2022 Oct; 12(10): 2217-2231

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.128

Article Details

How to Cite
Stein Gold, L., Pinter, A., Armstrong, A., Iversen, L., Praestegaard, M., & Augustin, M. (2023). Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream. SKIN The Journal of Cutaneous Medicine, 7(2), s128. https://doi.org/10.25251/skin.7.supp.128
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Posters from 2023 WCH Dermatology Conference: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>